The FDA approved Novocure's Optune Pax for locally advanced pancreatic cancer with gemcitabine and nab-paclitaxel, based on PANOVA-3 data showing improved overall survival. The device also earned a CE mark in Europe, with a planned launch in Germany.
The FDA has approved Optune Pax, a Tumor Treating Fields device, for use with chemotherapy in locally advanced pancreatic cancer. The approval is based on phase 3 trial data showing improved overall survival and pain progression outcomes. This marks the first new treatment approach for this patient population in approximately 30 years.
The FDA has approved Novocure's Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment for this patient group in decades. A trial of 571 patients showed a two-month improvement in overall survival when combined with chemotherapy.
Major pharmaceutical companies are highlighting their drug pipelines to offset upcoming patent losses, while Moderna confronts FDA rejection of its flu vaccine. The industry faces significant revenue challenges from patent cliffs in 2026.
The FDA approved Novocure's Optune Pax device for locally advanced pancreatic cancer treatment alongside chemotherapy, marking the first new treatment option in this indication since 1996. Phase III trial data showed statistically significant survival improvement.
The FDA has approved Optune Pax, a wearable device delivering tumor treating fields for locally advanced pancreatic cancer. The approval marks the first new treatment modality for this indication in nearly 30 years.
The FDA approved Optune Pax, a wearable Tumor Treating Fields device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The approval marks the first new treatment for this indication in nearly 30 years.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07587827 |
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE1 |
| NCT07429643 |
Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer. |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07407231 |
Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC) |
RECRUITING | NA |
| NCT07325214 |
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer |
NOT_YET_RECRUITING | NA |
| NCT07173374 |
Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study |
SUSPENDED | PHASE1 |
| NCT06944587 |
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer |
RECRUITING | |
| NCT06761027 |
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT06755359 |
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer |
RECRUITING | NA |
| NCT06669078 |
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT06494514 |
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer |
RECRUITING | NA |
